Skip to main content
Smart Investors Daily
GE HealthCare Technologies Inc. logo

NASDAQ · GEHC

GE HealthCare Technologies Inc.

Healthcare · Medical - Healthcare Information Services

$81.89

Down-$1.77 (-2.12%)

Updated Nov 20, 2026, 2:16 AM

SID Score

6.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
39.32B
P/E ratio
17.72
Dividend yield
0.21%
52-week range
$58.75 – $87.56
Volume
2.84M
Avg. volume
3.65M

Price performance · GEHC

GEHC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

GEHC closed at $81.89 after 21 trading sessions, up 14.66% for the selected period.

Last close
$81.89
Period change
+14.66%
Period low
$71.11
Period high
$85.81
Daily close
View OHLC price history
GEHC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$83.66$84.05$81.53$81.892.84M
Nov 18, 2026$81.31$83.99$81.13$83.663.65M
Nov 17, 2026$82.49$83.65$81.79$81.842.92M
Nov 16, 2026$83.46$84.11$82.73$82.963.49M
Nov 13, 2026$82.43$83.09$81.84$83.022.4M
Nov 12, 2026$82.01$83.22$81.42$81.842.67M
Nov 11, 2026$83.15$83.425$82.35$82.603.49M
Nov 10, 2026$83.58$83.91$82.44$83.652.98M
Nov 9, 2026$83.00$84.66$81.76$84.034.24M
Nov 6, 2026$81.71$83.27$81.4926$82.384.18M
Nov 5, 2026$86.25$87.24$82.715$83.756.23M
Nov 4, 2026$82.97$87.56$82.89$85.819.61M
Nov 3, 2026$79.42$80.81$78.955$80.665.49M
Nov 2, 2026$77.54$80.34$77.375$79.554.78M
Oct 30, 2026$77.43$78.22$76.195$76.573.97M
Oct 29, 2026$76.20$77.33$75.40$76.424.65M
Oct 28, 2026$76.00$77.88$74.64$75.829.57M
Oct 27, 2026$71.73$71.8025$70.17$71.115.06M
Oct 26, 2026$71.19$72.30$71.00$71.982.87M
Oct 23, 2026$70.74$71.86$70.095$71.452.98M
Oct 22, 2026$69.325$71.70$69.31$71.423.13M

Latest GEHC news

The latest Smart Investors Daily articles mentioning GEHC.

GEHC research

Overview

Company profile and research snapshot.

Company profile

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$88.17
Implied upside
—
Analysts
—
GEHC recent ratings
DateFirmRatingTarget
Nov 18, 2026BTIGBuy—
Nov 11, 2026Argus ResearchBuy—
Nov 3, 2026UBSNeutral—
Oct 29, 2026JP MorganNeutral—
Oct 29, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 26, 2026

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

CHICAGO, March 26, 2026--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI

Benzinga · Mar 26, 2026

GE HealthCare Announces Role In New COMPASS Consortium

GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.